Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728681 | 1.00 | CTSK (0.47) | CTSKCTSSSMN1; SMN2PPARAPPARG | |
| SCHEMBL212773 | 1.00 | CTSK (0.47) | CTSKCTSSSMN1; SMN2PPARAPPARG | |
| SCHEMBL21904767 | 0.87 | CTSK (0.44) | CTSKCTSSSMN1; SMN2CTSLCTSB | |
| SCHEMBL15083313 | 0.87 | SMN1; SMN2 (0.49) | CTSKCTSSSMN1; SMN2CTSLCTSB | |
| SCHEMBL4038634 | 0.87 | SMN1; SMN2 (0.46) | CTSKCTSSSMN1; SMN2CTSLCTSB | |
| SCHEMBL16289367 | 0.87 | SMN1; SMN2 (0.49) | CTSKCTSSSMN1; SMN2CTSLCTSB | |
| SCHEMBL4038638 | 0.87 | SMN1; SMN2 (0.46) | CTSKCTSSSMN1; SMN2CTSLCTSB | |
| SCHEMBL2179710 | 0.86 | GRIK1 (0.44) | CTSKCTSSSMN1; SMN2PPARAPPARG | |
| SCHEMBL29273137 | 0.86 | GRIK1 (0.44) | CTSKCTSSSMN1; SMN2PPARAPPARG | |
| SCHEMBL13571099 | 0.86 | GRIK1 (0.44) | CTSKCTSSSMN1; SMN2PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300395-B1 | 4-SUBSTITUTED PIPERIDINE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2009-09-02 | — | — | EP | claimed |
| US-20050026895-A1 | 4-Substituted piperidine compound | EISAI CO., LTD. | 2005-02-03 | — | — | US | claimed |
| US-20030166925-A1 | 4-Substituted piperidine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1300395-A1 | 4-SUBSTITUTED PIPERIDINE COMPOUND | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | RECLUDIX PHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-1261610-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| US-6423869-B1 | BACTERICIDES, ANTIULCER AGENTS | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2002-07-23 | — | — | US | disclosed |
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| EP-1149843-A1 | SUBSTITUTED PHENETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-10-31 | — | — | EP | disclosed |
| WO-2001060826-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-08-23 | — | — | WO | disclosed |
| CN-1304447-A | Treatment of parasitic diseases by inhibition of cysteine proteases of papain superfamily | SMITHKLINE BEECHAM CORP (US) | 2001-07-18 | — | — | CN | disclosed |
| US-5508466-A | REACTING MIXTURE OF N-PROTECTED-ALPHA-SUBSTITUTED-GLYCINE CATION DERIVATIVE AND ELEMENTAL ZINC WITH ORGANIC HALIDE IN POLAR SOLVENT | G.D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | CTSK 85/4885CTSS 213/4885SMN1; SMN2 3689/4885 |
| US-20050026895-A1 | 4-Substituted piperidine compound | ACHE, CHRM2, CHRM1 | CTSK 1517/4885CTSS 1315/4885SMN1; SMN2 1984/4885 |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | STAT6, STAT5A, STAT3 | CTSK 2775/4885CTSS 3327/4885SMN1; SMN2 4276/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885SMN1; SMN2 271/4885 |
| US-20030166925-A1 | 4-Substituted piperidine compound | ACHE, CHRM4, CHRM1 | CTSK 1336/4885CTSS 1370/4885SMN1; SMN2 1815/4885 |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | CTSK 64/4885CTSS 4/4885SMN1; SMN2 4763/4885 |
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | APP, APH1A, APH1B | CTSK 1372/4885CTSS 332/4885SMN1; SMN2 382/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CTSK 188/4885CTSS 273/4885SMN1; SMN2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.